# PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

> **NCT04353037** · PHASE2 · TERMINATED · sponsor: **UnitedHealth Group** · enrollment: 39 (actual)

## Conditions studied

- Coronavirus
- Corona Virus Infection

## Interventions

- **DRUG:** Group 1 HCQ
- **DRUG:** Group 2 Placebo

## Key facts

- **NCT ID:** NCT04353037
- **Lead sponsor:** UnitedHealth Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-07
- **Primary completion:** 2020-07-11
- **Final completion:** 2020-07-11
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.
- **Last updated:** 2021-10-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04353037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04353037, "PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04353037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*